Bay Area cryballoon ablation startup C2 Therapeutics just raised $11.6 million, according to a regulatory filing.
The company’s Coldplay Focal Cryoballoon Ablation System is meant to treat Barrett’s Esophagus – a fairly asymptomatic condition in which the tissue lining the esophagus gets replaced by a different kind of tissue – the sort that is found in the intestinal system. It’s most seen in people with acid reflux issues. Without treatment, a portion of these folks are at risk for a rare kind of cancer called esophageal adenocarcinoma.
C2’s device is administered through a scope, and expands as a balloon catheter that’s simultaneously inflated and cooled by an inert refrigerant delivered through a small, handheld unit, the company said. The balloon then conforms to the shape of the esophagus.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company’s raised about $10 million since 2007, according to regulatory filings.
[Photo from Flickr user zzzack]